Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-0.25%-4.10%+38.38%+92.61% 68.21B
+0.70%-0.58%+47.26%+87.91% 64.25B
-0.25%-1.92%-10.72%+436.70% 26.54B
+0.33%-10.61%+1.95%-16.27% 25.61B
+0.44%-2.23%+30.87%-19.04% 19.88B
-6.09%-12.08%+226.11%+375.00% 17.13B
+0.41%-5.51%-1.36%+533.35% 14.93B
+4.12%+0.30%+52.03%+150.18% 14.1B
-0.24%+5.18%+23.04%+190.97% 12.45B
Average -0.06%-3.92%+45.28%+203.49% 29.23B
Weighted average by Cap. +0.00%-3.22%+41.46%+158.27%
Logo Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc is a Canada-based biotechnology company. The Company develops pharmaceutical products in the areas of infectious disease and oncology. Thallion Pharmaceuticals Inc's lead clinical program, Shigamabs, is a dual antibody product for the treatment of Shiga toxin-producing E. coli bacterial infections and has completed a Phase II clinical trial. The Company is a subsidiary of BELLUS Health.
Employees
-